Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2016 - 2025)

Sonoma Pharmaceuticals has reported Net Income towards Common Stockholders over the past 16 years, most recently at -$819000.0 for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 11.75% year-over-year to -$819000.0; the TTM value through Dec 2025 reached -$3.4 million, up 10.09%, while the annual FY2025 figure was -$3.5 million, 28.5% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$819000.0 at Sonoma Pharmaceuticals, down from -$534000.0 in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$100000.0 in Q3 2021 and troughed at -$1.9 million in Q4 2022.
  • A 5-year average of -$1.0 million and a median of -$1.0 million in 2022 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: plummeted 917.0% in 2022 and later skyrocketed 58.89% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$100000.0 in 2021, then plummeted by 1839.0% to -$1.9 million in 2022, then soared by 55.34% to -$866000.0 in 2023, then dropped by 7.16% to -$928000.0 in 2024, then grew by 11.75% to -$819000.0 in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for SNOA at -$819000.0 in Q4 2025, -$534000.0 in Q3 2025, and -$1.2 million in Q2 2025.